Biocept Aktie

Biocept AAQS

Delisted

AAQS'en for Biocept (BIOC) pr. 18. aug. 2026 er 5. I foregående år var AAQS'en 5,00 — en ændring på 0,00 % (lavere).

AAQS

5

YoY

0,00%

Senest opdateret:

Biocept har en aktuel AAQS på 5. En høj AAQS kan betragtes som et positivt tegn på, at virksomheden udvikler sig succesfuldt. Investorerne kan forvente, at virksomheden er på rette spor mod at skabe overskud. På den anden side er det vigtigt at betragte AAQS for aktien Biocept i forhold til de opnåede overskud og sammenligne med andre virksomheder i samme branche. En høj AAQS er ikke en absolut garanti for en positiv fremtid. Det er kun på den måde, man kan få et komplet billede af virksomhedens præstationer. For bedre at kunne vurdere virksomhedens udvikling er det vigtigt at betragte AAQS i sammenligning med andre virksomheder i samme branche. Generelt bør investorer altid betragte en virksomheds AAQS i sammenhæng med andre nøgletal som overskud, EBIT, cash flow og andre for at træffe en velbaseret investeringsbeslutning.
Access this data via the Eulerpool API

Biocept Aktieanalyse

Hvad laver Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Biocept aktie

AAQS'en for Biocept er 5 i 2026.

På Eulerpool kan du finde den fuldstændige historiske udvikling af AAQS'en Biocept siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

AAQS er en nøgletal udviklet af AlleAktien.

AAQS er en nøgletal udviklet af AlleAktien.

Access this data via the Eulerpool API

Kvalitet — Biocept

Alle nøgletal — Biocept